Published in Am Rev Respir Dis on December 01, 1990
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40
Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn (2007) 1.77
Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.73
Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest (2011) 1.67
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Clinical relevance of KRAS in human cancers. J Biomed Biotechnol (2010) 1.34
The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene (2009) 1.22
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol (2014) 1.20
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res (2008) 1.09
Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma. Mol Cancer (2013) 1.04
Wnt and Kras signaling-dark siblings in lung cancer. Oncotarget (2011) 0.95
Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol (1996) 0.94
Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells. J Biomol Screen (2009) 0.93
KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget (2016) 0.91
Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg (2013) 0.90
Mutation of the LXCXE binding cleft of pRb facilitates transformation by ras in vitro but does not promote tumorigenesis in vivo. PLoS One (2013) 0.87
Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med (2008) 0.86
Targeting filamin A reduces K-RAS-induced lung adenocarcinomas and endothelial response to tumor growth in mice. Mol Cancer (2012) 0.85
Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Neoplasia (2009) 0.84
Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway inflammation. Mol Cancer (2012) 0.84
The antibiotic azatyrosine suppresses progesterone or [Val12]p21 Ha-ras/insulin-like growth factor I-induced germinal vesicle breakdown and tyrosine phosphorylation of Xenopus mitogen-activated protein kinase in oocytes. Proc Natl Acad Sci U S A (1992) 0.80
Amplification of Cellular Oncogenes in Solid Tumors. N Am J Med Sci (2015) 0.76
Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value. Clin Lung Cancer (2015) 0.76
Inhibitory effect of flavonoids on mutant H-Rasp protein. Bioinformation (2010) 0.75
Interaction between smoking and asbestos in human lung adenocarcinoma: role of K-ras mutations. Environ Health Perspect (1993) 0.75
Rap2a serves as a potential prognostic indicator of renal cell carcinoma and promotes its migration and invasion through up-regulating p-Akt. Sci Rep (2017) 0.75
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res (1988) 3.91
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A (1993) 3.32
K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res (1996) 2.29
Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res (1993) 1.92
Clinical significance of ras oncogene activation in human lung cancer. Cancer Res (1992) 1.69
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer (1991) 1.47
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest (1994) 1.13
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol (2009) 1.12
p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol (1993) 1.09
Expression of insulin-like growth factor-I and -II genes in human smooth muscle tumours. EMBO J (1988) 1.08
Multiple hyperplastic polyps in the stomach: evidence for clonality and neoplastic potential. Gastroenterology (1997) 1.05
Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol (1993) 1.04
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol (1997) 1.03
Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol (1996) 0.98
Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol (1988) 0.96
K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer (1998) 0.95
Clinical significance of K-ras oncogene activation in ampullary neoplasms. J Clin Pathol (1996) 0.88
Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients. Am J Pathol (1997) 0.87
Expression of insulin-like growth factor-I and -II genes in rat medullary thyroid carcinoma. FEBS Lett (1987) 0.85
Expression of the second calcitonin/calcitonin gene-related peptide gene in Ewing sarcoma cell lines. J Clin Endocrinol Metab (1987) 0.82
Mutational analysis of the P16-binding domain of cyclin-dependent kinase 4 in tumors in the head region of the pancreas. Pancreas (1998) 0.79
Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein. Biochem Biophys Res Commun (1998) 0.78
Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations. Gut (1997) 0.77
Radiosensitivity of small-cell lung cancer xenografts compared with activity of c-myc, N-myc, L-myc, c-raf-1 and K-ras proto-oncogenes. Int J Cancer (1991) 0.77
High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer. Cancer J (2000) 0.75
Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers. Eur J Cancer Clin Oncol (1988) 0.75
[Molecular-genetic detection of colorectal carcinoma in the feces]. Ned Tijdschr Geneeskd (1995) 0.75